Ono Pharmaceutical Co. (OPHLF)
(Delayed Data from OTC)
$13.36 USD
-1.34 (-9.11%)
Updated Aug 29, 2024 01:32 PM ET
2-Buy of 5 2
B Value C Growth C Momentum B VGM
Cash flow Statements
Fiscal Year End for Ono Pharmaceutical Co falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 1,129.77 | 1,062.14 | 934.72 | 948.37 | 733.20 |
Depreciation/Amortization & Depletion | 125.17 | 129.14 | 157.72 | 148.71 | 130.77 |
Net Change from Assets/Liabilities | -199.81 | 10.63 | -267.95 | -61.24 | 45.28 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -291.57 | -20.77 | -274.22 | -340.46 | -227.00 |
Net Cash From Operating Activities | 763.55 | 1,181.11 | 550.28 | 695.38 | 682.24 |
Property & Equipment | -21.51 | -39.47 | -48.80 | -65.95 | -64.87 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 708.09 | 395.37 | 689.35 | 414.29 | 526.60 |
Other Investing Activities | -354.85 | -1,097.81 | -586.80 | -889.64 | -555.88 |
Net Cash from Investing Activities | 331.73 | -741.92 | 53.74 | -541.31 | -94.15 |
Uses of Funds
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -345.07 | -0.01 | -267.06 | -0.03 | -272.17 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -18.25 | -20.22 | -22.78 | -21.58 | -21.69 |
Payment of Dividends & Other Distributions | -256.62 | -220.14 | -246.26 | -211.08 | -209.56 |
Other Financing Activities | 0.00 | 0.00 | -0.04 | -0.06 | -0.03 |
Net Cash from Financing Activities | -619.95 | -240.38 | -536.11 | -232.69 | -503.43 |
Effect of Exchange Rate Changes | 7.70 | 1.15 | 3.88 | 3.79 | -1.65 |
Net Change In Cash & Equivalents | 483.04 | 199.97 | 71.80 | -74.82 | 83.02 |
Cash at Beginning of Period | 663.33 | 511.43 | 543.30 | 648.65 | 551.83 |
Cash at End of Period | 1,146.37 | 711.40 | 615.10 | 573.82 | 634.85 |
Diluted Net EPS | 1.84 | 1.71 | 1.44 | 1.42 | 1.09 |
Fiscal Year End for Ono Pharmaceutical Co falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 1,129.77 | NA | 685.14 | 309.36 |
Depreciation/Amortization & Depletion | NA | 125.17 | NA | 62.69 | 33.07 |
Net Change from Assets/Liabilities | NA | -199.81 | NA | -286.07 | -180.73 |
Net Cash from Discontinued Operations | NA | 0.00 | NA | NA | 0.00 |
Other Operating Activities | NA | -291.57 | NA | -208.39 | -232.04 |
Net Cash From Operating Activities | NA | 763.55 | NA | 253.37 | -70.36 |
Property & Equipment | NA | -21.51 | NA | -11.51 | -6.09 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | NA | NA | 0.00 |
Investments | NA | 708.09 | NA | 423.36 | -6.37 |
Other Investing Activities | NA | -354.85 | NA | -268.93 | -54.63 |
Net Cash from Investing Activities | NA | 331.73 | NA | 142.92 | -67.09 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | -345.07 | NA | -187.59 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | NA | NA | 0.00 |
Increase (Decrease) Short-Term Debt | NA | -18.25 | NA | -9.67 | -5.11 |
Payment of Dividends & Other Distributions | NA | -256.63 | NA | -124.60 | -122.90 |
Other Financing Activities | NA | 0.00 | NA | NA | 0.00 |
Net Cash from Financing Activities | NA | -619.95 | NA | -321.86 | -128.01 |
Effect of Exchange Rate Changes | NA | 7.70 | NA | 5.40 | 4.83 |
Net Change In Cash & Equivalents | NA | 483.04 | NA | 79.83 | -260.62 |
Cash at Beginning of Period | NA | 663.33 | NA | 663.33 | 701.79 |
Cash at End of Period | NA | 1,146.37 | NA | 743.16 | 441.16 |
Diluted Net EPS | 0.34 | 0.25 | 0.51 | 0.61 | 0.48 |